EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency

Xanthippi Tseretopoulou iD, Jiajia Chen, Angela Lucas-Herald, Evangelia Charmandari, Jin-Ho Choi, Xinyu Dou, Rasha Hamza, Jamie Harvey, Andrew R Hoffman iD, Reiko Horikawa iD, Gudmundur Johannsson iD, Alexander Augusto de Lima Jorge und 8 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf500 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Xanthippi Tseretopoulou und 19 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital for Children, Glasgow G51 4TF, UK. Hauptthemen laut MEDLINE: Human Growth Hormone, Growth Disorders, Hormone Replacement Therapy, Dwarfism, Pituitary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GeneScience Pharmaceutical Co Ltd, Novo Nordisk, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Although the safety and effectiveness of recombinant human growth hormone therapy (rhGH) has been reported for several years, the level of consensus on the outcomes that should be reported is unclear.

Objective

This work aims to understand the frequency and trends in reported outcomes of safety and effectiveness for rhGH therapy for growth hormone deficiency (GHD) in childhood.

Methods

A systematic review was performed in 7 English- and Chinese-language databases. Eligibility criteria included all studies published between 2003 and 2022, with participants who started rhGH before age 16 years for GHD.

Results

The 219 eligible studies that were identified included 171 cohort studies, 39 controlled trials, and 9 case-control studies. The median age of the participants at start of rhGH was 9.5 years (10th-90th: 7.1-11.9). The most commonly reported outcomes included change in height SDS in 117 (53%), height velocity in 105 (48%), insulin-like growth factor-1 (IGF-1) in 66 (30%), height in 63 (29%), bone age in 58 (26%), IGF-1 SDS in 45 (21%), injection site adverse events in 44 (20%), glucose concentration in 42 (19%), insulin-like growth factor-binding protein 3 in 34 (16%), and thyroid function in 30 (14%). Of the 342 different outcomes, 178 (52%) were considered as outcomes that were mainly focused on safety, 94 (28%) on efficacy, and 70 (20%) on both. Over the two decades, height SDS and height velocity remained the most frequently reported outcomes. Of the 342 outcomes, 9 (3%) were on quality of life and these were reported in 29 of 219 (13%) studies.

Conclusion

The results of this systematic review allow the development of a core outcome set that is recommended for routine use in all children receiving rhGH for childhood GHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneGrowth DisordersHormone Replacement TherapyDwarfism, PituitaryHumansChildBody HeightTreatment OutcomeAdolescentInsulin-Like Growth Factor IRecombinant Proteins

Stichwörter der Autor:innen

core outcomeseffectivenessgrowth hormonesafety

Substanzen

Human Growth HormoneInsulin-Like Growth Factor IRecombinant Proteins

Autor:innen und Institutionen

  • Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital for Children, Glasgow G51 4TF, UK.
  • Office for Rare Conditions, University of Glasgow, Glasgow G51 4TF, UK.
  • Beijing Children's Hospital, The Capital Medical University, National Center for Children's Health, Beijing 100044, China.
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, 'Aghia Sophia' Children's Hospital, Athens 11527, Greece.
  • Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
  • Department of Pediatrics, Pediatric Endocrinology Unit, Ain Shams University, Cairo 1181, Egypt.

ORCID-Profile: Xanthippi Tseretopoulou, Andrew R Hoffman, Reiko Horikawa, Gudmundur Johannsson, Lars Sävendahl, S Faisal Ahmed

Förderung

  • GeneScience Pharmaceutical Co Ltd
  • Novo Nordisk
  • Pfizer
  • Neurocrine Biosciences
  • NHS Research Scotland

Zitieren

APA

Tseretopoulou, X., Chen, J., Lucas-Herald, A., Charmandari, E., Choi, J. H., Dou, X., Hamza, R., Harvey, J., Hoffman, A. R., Horikawa, R., Johannsson, G., de Lima Jorge, A. A., Miller, B. S., Pietropoli, A., Sävendahl, L., Vitali, D., Wajnrajch, M., Chen, S. C., Gong, C., & Ahmed, S. F. (2026). Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf500

Vancouver

Tseretopoulou X, Chen J, Lucas-Herald A, Charmandari E, Choi JH, Dou X, et al. Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf500

BibTeX
@article{Tseretopoulou2026,
  author = {Tseretopoulou, Xanthippi and Chen, Jiajia and Lucas-Herald, Angela and Charmandari, Evangelia and Choi, Jin-Ho and Dou, Xinyu and Hamza, Rasha and Harvey, Jamie and Hoffman, Andrew R and Horikawa, Reiko and Johannsson, Gudmundur and de Lima Jorge, Alexander Augusto and Miller, Bradley S and Pietropoli, Alberto and Sävendahl, Lars and Vitali, Diana and Wajnrajch, Michael and Chen, Suet Ching and Gong, Chunxiu and Ahmed, S Faisal},
  title = {Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf500}
}
Kostenlos starten →